Polymorphisms Associated with Adalimumab and Infliximab Response in Moderate-to-severe Plaque Psoriasis
Overview
Pharmacology
Authors
Affiliations
Aim: This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab.
Materials & Methods: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis.
Results: Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months.
Conclusion: Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.
Al-Sofi R, Bergmann M, Nielsen C, Andersen V, Skov L, Loft N Int J Mol Sci. 2024; 25(11).
PMID: 38891983 PMC: 11171831. DOI: 10.3390/ijms25115793.
Krusic M, Jezernik G, Potocnik U Pharmaceutics. 2023; 15(8).
PMID: 37631238 PMC: 10459906. DOI: 10.3390/pharmaceutics15082024.
Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.
Berna-Rico E, Perez-Bootello J, Abbad-Jaime de Aragon C, Gonzalez-Cantero A Int J Mol Sci. 2023; 24(12).
PMID: 37372997 PMC: 10298473. DOI: 10.3390/ijms24129850.
Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.
Antonatos C, Asmenoudi P, Panoutsopoulou M, Vasilopoulos Y Int J Mol Sci. 2023; 24(8).
PMID: 37108251 PMC: 10139144. DOI: 10.3390/ijms24087090.
Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
Corbett M, Ramessur R, Marshall D, Acencio M, Ostaszewski M, Barbosa I Br J Dermatol. 2022; 187(4):494-506.
PMID: 35606928 PMC: 9796396. DOI: 10.1111/bjd.21677.